Intellia Therapeutics, Inc. (NTLA) incurred second-quarter 2024 loss of 1.31pershare(excludingaone−timeexpenseofchangeinfairvalueofinvestments),whichwaswiderthantheZacksConsensusEstimateofalossof1.21. In the year-ago quarter, Intellia had incurred a loss of 1.40pershare.Includingtheaboveone−timeexpense,thecompanyreportedalossof1.52 per share in the second quarter of 2024. The company's total revenues currently comprise only collaboration revenues. NTLA reported re ...